Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) combine the specificity of antibodies with the potency of
small molecules to create targeted drugs. Despite the simplicity of this concept, generation of …

Immunoglobulin (IgG) glycosylation is a complex enzymatically controlled process, essential
for the structure and function of IgG. IgG glycome is relatively stable in the state of …

Critical quality attributes (CQA) are physical, chemical, biological or microbiological
properties or characteristics that must be within an appropriate limit, range or distribution to …

Here, we review the current state of the art in analytical and structural methods used to
characterize therapeutic monoclonal antibodies (mAbs) and derivatives. First, a general …

NK cells have therapeutic potential for a wide variety of human malignancies. However,
because NK cells expand poorly in vitro, have limited life spans in viv o, and represent a …

Escherichia coli is the most preferred microorganism to express heterologous proteins for
therapeutic use, as around 30% of the approved therapeutic proteins are currently being …

Nearly 30% of currently approved recombinant therapeutic proteins are produced in
Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield …

Healthy immune responses require efficient protection without excessive inflammation.
Recent discoveries on the degree of fucosylation of a human N-linked glycan at a conserved …

Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy
of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to …